Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors (ICIs) have transformed the treatment of bladder cancer (BC) and renal cell carcinoma (RCC), whereas prostate cancer (PC) remains intrinsically insensitive to ICIs. In patients with BC and RCC, primary and acquired resistance remain formidable clinical challenges. Transforming growth factor‑β (TGF‑β) signaling has emerged as a contributor to immunotherapy refractoriness through its multifaceted remodeling of the tumor immune microenvironment. This pathway orchestrates CD8+ T cell exhaustion, regulatory T cell expansion, macrophage polarization toward immunosuppressive phenotypes, cancer‑associated fibroblast activation with consequent extracellular matrix remodeling, and metabolic reprogramming that sustains a tolerogenic niche. In patients with BC, PC and RCC, TGF‑β pathway activation is correlated with immune exclusion and poor responses to immune checkpoint blockade. Although TGF‑β‑targeted agents, including ligand‑neutralizing antibodies, receptor kinase inhibitors, and TGF‑β‑resistant cellular immunotherapies, have shown encouraging preclinical and early clinical activity, challenges persist regarding on‑target toxicity, the context‑dependent dual functionality of TGF‑β, and the lack of validated predictive biomarkers for patient selection. The present review comprehensively summarizes the mechanisms underlying of TGF‑β‑mediated immune evasion in urological malignancies, critically evaluates current therapeutic strategies and their limitations, and discusses emerging approaches to overcome resistance, thereby informing the rational design of TGF‑β‑targeted immunotherapies.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: